LONDON, ONTARIO and BOSTON, MASSACHUSETTS--(Marketwired - Sept. 7, 2017) - Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that Alison Silva, President and Chief Executive Officer, will co-chair the Global Genes RARE Partnering & Investor Forum on Thursday, September 14, 2017 in Irvine, CA.

At the Global Genes RARE Partnering & Investor Forum, Ms. Silva will also moderate a panel discussion, entitled "Innovation Company Creation Models for Rare Diseases." The panel is comprised of company executives and investors highly regarded for their roles in the creation of innovative companies focused on the development of treatments for rare diseases. The panel will discuss the evolving landscape of rare disease drug discovery and development, with a focus on innovative investment strategies. Topics will include the successes and pitfalls of new rare disease funding models, as well as the emerging drivers and trends in a field that has received growing attention from pharmaceutical companies, venture investors, government agencies, and patient advocates.

"It is an honor to be selected as a co-chair for this meeting, and I am excited to moderate this discussion focused on novel and innovative strategies new rare disease companies can employ as well as facilitate a discussion from our panelists on their models for new company creation in this space," said Alison Silva, President and Chief Executive Officer. "Our lead candidate, COTI-2, is currently in a Phase 1 trial for the treatment of orphan oncology indications. Our progress advancing COTI-2 to clinical trials underscores the important role innovative companies play in the development of effective new treatments for patients suffering from rare diseases."

About Critical Outcome Technologies Inc.

COTI is a clinical stage biotech company that uses proprietary artificial intelligence technologies to pursue a targeted and transformational approach to treating cancer and other unmet medical needs. COTI's CHEMSAS® technology accelerates the discovery and development of novel drug therapies, allowing the Company to build a pipeline of potential drug candidates faster and with a higher probability of success than traditional methods.

The Company's lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. P53 mutations occur in over 50% of all cancers. COTI-2 is initially being evaluated for the treatment of gynecologic cancers and head and neck squamous cell carcinoma in a Phase 1 clinical trial at the MD Anderson Cancer Center at the University of Texas and the Lurie Cancer Center at Northwestern University. The Company has secured orphan drug status in the United States for COTI-2 for the treatment of ovarian cancer. Preclinical data suggests that COTI-2 could dramatically improve the treatment of cancers with mutations in the p53 gene.

The Company's second lead compound, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function. KRAS mutations occur in up to 30% of all cancers and represent a tremendous unmet clinical need and a desirable drug target. COTI-219 is undergoing IND-enabling studies to support a regulatory submission in early 2018.

Follow @CriticalOutcome on Twitter at

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, visit

Contact Information:

Alison Silva
President and CEO